In Alzheimer’s disease (AD), the
major pathological hallmarks are β-sheet
aggregates of β-amyloid peptides in senile plaques
and hyperphosphorylated tau protein in neurofibrillary tangles (NFT).1-2
AnaSpec, a provider of one of the world’s largest collections
of β-amyloid peptides, also provides the industry’s largest collection
of anti-Tau antibodies - 23 phosphospecific and 14 non-phosphospecific Tau antibodies.
Custom service for production of AD
related peptides and antibodies is also available. For more information, please click
here.
These Tau rabbit polyclonal
antibodies, raised against Tau peptides, are supplied as epitope-affinity purified
rabbit IgG at 25 or 50 μg sizes at 0.2 mg/ml of 1x PBS solution. They have been validated in dot blots and IHC (Figure
1). Species reactivity includes human, mouse and rat. Some antibodies have also
shown reactivity with bovine, chicken and zebrafish. AnaSpec gratefully acknowledges Dr. Claudia
Schwab for performing the Anti-Tau antibodies IHCs (in Dr. Patrick McGeer’s
lab, University of British Columbia, Vancouver, BC, Canada).
Tau is a collection of microtubule-associated proteins that
is involved in microtubule assembly and stabilization.3 In adult human brain, 6 isoforms, ranging between 352 and
441 amino acids in length, are produced as a result of alternative RNA splicing.4-5 The expression of Tau isoforms is developmentally regulated,
as only the smallest Tau polypeptide is expressed in the fetal brain. Hyperphosphorylated
Tau is the major component of the paired helical filament of Alzheimer’s disease.
Anti-phospho-Tau antibodies are used to identify specific amino acids that are
phosphorylated in Tau from normal brains and Alzheimer’s disease brains. The
Tau proteins, especially in developing brains and in Alzheimer brains, are phosphorylated
in vivo at many different sites such as Thr181, Ser198, Ser199, Ser202, Thr205,
Thr212, Ser214, Thr217, Thr231, Ser235, Ser262, Ser356, Ser396, Ser400, Ser404
and Ser413.6-7
Complementing one of the world’s most comprehensive collections of β-amyloid
peptides, the availability of these anti-Tau antibodies demonstrates AnaSpec’s
commitment to delivering integrated solutions for Alzheimer research.

Figure 1. IHCs of Anti-Tau, phosphorylated and non-phosphorylated
antibodies. All antibodies strongly label neurofibrillary tangles (NFT), dystrophic
neurites (DN) in neuropil and plaques, neuropil threads (NPT), and some glia
cells in white matter in AD tissue (images courtesy of Dr. C. Schwab, Univ of
British Columbia, Vancouver, Canada).

Figure 2. Dot blot of Tau antibodies.
Click here
for more information.
Table 1. A full listing of AnaSpec’s Tau Antibodies
| Product |
50 ug |
25 ug |
| Anti-Tau
|
53884 |
NA |
| Anti-Tau
(pThr181) |
54960 |
54960-025 |
| Anti-Tau
(paired181) |
54961 |
54961-025 |
| Anti-Tau
(pSer198) |
54962 |
54962-025 |
| Anti-Tau
(pSer184) |
55413 |
55413-025 |
| Anti-Tau
(pSer195) |
55414 |
55414-025 |
| Anti-Tau
(paired195) |
55460 |
55460-025 |
| Anti-Tau
(pSer198) |
55962 |
55962-025 |
| Anti-Tau
(pSer199, 202) |
54963 |
54963-025 |
| Anti-Tau
(pSer202) |
28017 |
28017-025 |
| Anti-Tau
(paired202) |
28018 |
28018-025 |
| Anti-Tau
(pThr205) |
54964 |
54964-025 |
| Anti-Tau
(paired198, 199, 202, 205) |
54965 |
54965-025 |
| Anti-Tau
(pThr212) |
54966 |
54966-025 |
| Anti-Tau
(pSer214) |
54967 |
54967-025 |
| Anti-Tau
(pThr217) |
54968 |
54968-025 |
| Anti-Tau
(paired212, 214, 217) |
54969 |
54969-025 |
| Anti-Tau
(pThr231) |
55313 |
55313-025 |
| Anti-Tau
(paired231) |
55415 |
55415-025 |
| Anti-Tau
(pSer235) |
55315 |
55315-025 |
| Anti-Tau
(paired235) |
55461 |
55461-025 |
| Anti-Tau
(pSer237) |
55312 |
55312-025 |
| Anti-Tau
(paired237) |
55322 |
55322-025 |
| Anti-Tau
(pSer238) |
55323 |
55323-025 |
| Anti-Tau
(pSer262) |
54973 |
54973-025 |
| Anti-Tau
(paired262) |
54974 |
54974-025 |
| Anti-Tau
(pSer356) |
54975 |
54975-025 |
| Anti-Tau
(paired356) |
54976 |
54976-025 |
| Anti-Tau
(pSer396) |
54977 |
54977-025 |
| Anti-Tau
(pSer400) |
54978 |
54978-025 |
| Anti-Tau
(pSer404) |
28023 |
28023-025 |
| Anti-Tau
(paired404) |
28024 |
28024-025 |
| Anti-Tau
(paired396, 400, 404) |
54979 |
54979-025 |
| Anti-Tau
(pSer409) |
55417 |
55417-025 |
| Anti-Tau
(paired409, 412, 413) |
55416 |
55416-025 |
| Anti-Tau (pSer412) |
55418 |
55418-025 |
| Anti-Tau (pSer413) |
55325 |
55325-025 |
Table 2. Additional Alzheimer’s Disease related antibodies.
| Product |
Size |
Catalog # |
| Anti - α - Synuclein (paired 87) |
50 µg |
55330 |
| Anti - α - Synuclein (pSer 87) |
25 µg
50 µg |
55329-025
55329 |
| Anti - α -Synuclein (mouse) |
50 µg |
53877 |
| Anti - β -Synuclein |
50 µg |
53879 |
| Anti - β - Amyloid (1 - 40) |
50 µg |
54295 |
| Anti - β - Amyloid (1 - 40), mouse monoclonal |
50 µg |
55921 |
| Anti - β - Amyloid (1 - 42), mouse monoclonal |
50 µg |
55922 |
| Anti - β - Amyloid (NT), human |
50 µg |
53224 |
| Anti - β - Amyloid and BACE Sampler
Set |
1 Set |
54294 |
| Anti - APP (AbNT)
Amyoid
beta A4 protein precursor, Alzheimer’s disease amyloid protein |
50 µg |
54095 |
| Anti - APP (CT)
Amyoid
beta A4 protein precursor, Alzheimer’s disease amyloid protein |
50 µg |
54096 |
| Anti - APP (NT) |
50 µg |
53233 |
| Anti - APP (paired668) |
50 µg |
54980 |
| Anti - APP (pThr668) |
25 µg
50 µg |
54296-025
54296 |
| Anti - BACE (CT)
Beta -
site APP - cleaving enzyme Asp2 |
50 µg |
54101 |
| Anti - BACE2 (CT)
Beta -
site APP cleaving enzyme 2, Asp1, DRAP |
50 µg |
54100 |
| Anti - BACE2 (NT)
Beta -
site APP cleaving enzyme 2, Asp1, DRAP |
50 µg |
54099 |
| Anti - ERAB
Endoplasmic
Reticulum - associated β-Amyloid peptide |
50 µg |
53463 |
Related Products
Full listing
of Alzheimer’s disease related antibodies
World’s largest
selection of b-amyloid and related peptides
DHL™ β-amyloid
(1-40) Sampler Kit DHL™ β-amyloid
(1-42) Sampler Kit
SensoLyte® α-Secretase
Assay Kit
α-Synuclein
recombinant human protein
α-Synuclein
recombinant human protein, HiLyte Fluor™ 488 labeled (Ex/Em
= 490/520 nm)
β-Synuclein
recombinant human protein
Speedy
28-Day polyclonal antibody production service
References
1.Khachaturian,
ZS. Arch. Neurol. 42, 1097 (1985).
2.Mirra, SS. et al. Neurol. 41, 479 (1991).
3.Cleveland, DW. et al. J. Mol. Biol. 116, 207 (1977).
4.Goedert, M. et al. Neuron 3, 519 (1989).
5.Geodert, M. et al. EMBO J. 8, 393 (1989).
6.Billingsley, M. et al. Biochem J. 323, 577 (1997).
7.Hanger, DP. et al. J. Neurochem. 71, 2465. (1998).
|